Gelteq (GELS) Current Deferred Revenue (2024)
Gelteq's (GELS) quarterly Current Deferred Revenue came in at $77627.3 in Q4 2024, down 6.04% quarter-over-quarter from $82614.7 in Q2 2024.
Gelteq (GELS) Current Deferred Revenue (2024) Analysis & Trends
Gelteq's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $77627.3 for Q4 2024.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $77627.3 in Q4 2024; TTM through Dec 2024 was $77627.3, a N/A change from a year earlier, with the FY2024 full-year figure at $82614.7, changed N/A from the prior year.
- Current Deferred Revenue eased to $77627.3 in Q4 2024 per GELS's latest filing, from $82614.7 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $82614.7 in Q2 2024 and bottomed at $77627.3 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Gelteq | 740.00 | -47,821.64 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 77,627.26 |
| Jun 30, 2024 | 82,614.65 |